ImmuPharma PLC (UK) Performance
| IMM Stock | 1.47 0.08 5.16% |
ImmuPharma PLC has a performance score of 1 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.0463, which attests to not very significant fluctuations relative to the market. As returns on the market increase, ImmuPharma PLC's returns are expected to increase less than the market. However, during the bear market, the loss of holding ImmuPharma PLC is expected to be smaller as well. ImmuPharma PLC right now retains a risk of 2.97%. Please check out ImmuPharma PLC maximum drawdown, semi variance, and the relationship between the sortino ratio and potential upside , to decide if ImmuPharma PLC will be following its current trending patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in ImmuPharma PLC are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound technical and fundamental indicators, ImmuPharma PLC is not utilizing all of its potentials. The newest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 667.8 K |
ImmuPharma |
ImmuPharma PLC Relative Risk vs. Return Landscape
If you would invest 147.00 in ImmuPharma PLC on August 30, 2024 and sell it today you would earn a total of 0.00 from holding ImmuPharma PLC or generate 0.0% return on investment over 90 days. ImmuPharma PLC is generating 0.0449% of daily returns and assumes 2.9716% volatility on return distribution over the 90 days horizon. Simply put, 26% of stocks are less volatile than ImmuPharma, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
ImmuPharma PLC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ImmuPharma PLC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ImmuPharma PLC, and traders can use it to determine the average amount a ImmuPharma PLC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0151
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMM |
Estimated Market Risk
| 2.97 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average ImmuPharma PLC is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ImmuPharma PLC by adding it to a well-diversified portfolio.
ImmuPharma PLC Fundamentals Growth
ImmuPharma Stock prices reflect investors' perceptions of the future prospects and financial health of ImmuPharma PLC, and ImmuPharma PLC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ImmuPharma Stock performance.
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.43 | ||||
| Operating Margin | 36.15 % | ||||
| Current Valuation | 6.02 M | ||||
| Shares Outstanding | 416.44 M | ||||
| Price To Book | 2.31 X | ||||
| Price To Sales | 60.75 X | ||||
| EBITDA | (3.03 M) | ||||
| Total Debt | 1.67 M | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (1.36 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Total Asset | 2.72 M | ||||
| Retained Earnings | (64.08 M) | ||||
About ImmuPharma PLC Performance
By analyzing ImmuPharma PLC's fundamental ratios, stakeholders can gain valuable insights into ImmuPharma PLC's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ImmuPharma PLC has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ImmuPharma PLC has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about ImmuPharma PLC performance evaluation
Checking the ongoing alerts about ImmuPharma PLC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ImmuPharma PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ImmuPharma PLC may become a speculative penny stock | |
| ImmuPharma PLC has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (2.92 M) with profit before overhead, payroll, taxes, and interest of 118.35 K. | |
| ImmuPharma PLC generates negative cash flow from operations | |
| About 48.0% of the company shares are held by company insiders |
- Analyzing ImmuPharma PLC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ImmuPharma PLC's stock is overvalued or undervalued compared to its peers.
- Examining ImmuPharma PLC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ImmuPharma PLC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ImmuPharma PLC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ImmuPharma PLC's stock. These opinions can provide insight into ImmuPharma PLC's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ImmuPharma Stock analysis
When running ImmuPharma PLC's price analysis, check to measure ImmuPharma PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuPharma PLC is operating at the current time. Most of ImmuPharma PLC's value examination focuses on studying past and present price action to predict the probability of ImmuPharma PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuPharma PLC's price. Additionally, you may evaluate how the addition of ImmuPharma PLC to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |